Literature DB >> 6117307

A study of conjugation and drug elimination in the human neonate.

A J Cummings, A G Whitelaw.   

Abstract

1 An investigation has been made of the excretion of alpha-methyldopa, alpha-methyldopa sulphate, lorazepam and lorazepam glucuronide in the urine of neonates. 2 The rate of elimination of both the drugs in the newborn is slow compared with the adult rate, and apparent half-life being 3 to 4 times longer than the reported adult values. 3 The newborn appear able to readily metabolise alpha-methyldopa to alpha-methyldopa sulphate and to slowly conjugate lorazepam with glucuronic acid. alpha-Methyldopa tends to be conjugated to a greater extent and lorazepam to about the same or slightly lesser extent in the newborn than in adults. 4 It is postulated that elimination in the neonate is mainly controlled by the rate of renal excretion in the case of alpha-methyldopa and by the rate of conjugation in the case of lorazepam.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6117307      PMCID: PMC1401888          DOI: 10.1111/j.1365-2125.1981.tb01259.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam.

Authors:  D J Greenblatt; K Franke; R I Shader
Journal:  J Chromatogr       Date:  1978-09-01

2.  Estimation of plasma lorazepam by gas-liquid chromatography and a benzene extraction.

Authors:  P J Howard; J K Lilburn; J W Dundee; W Toner; P D McIlroy
Journal:  Anaesthesia       Date:  1977-09       Impact factor: 6.955

3.  Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans.

Authors:  D J Greenblatt; R I Shader; K Franke; D S MacLaughlin; J S Harmatz; M D Allen; A Werner; E Woo
Journal:  J Pharm Sci       Date:  1979-01       Impact factor: 3.534

4.  Placental passage of oxazepam and its metabolism in mother and newborn.

Authors:  G Tomson; N O Lunell; A Sundwall; A Rane
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

5.  Pharmacokinetics of methyldopa in man.

Authors:  K C Kwan; E L Foltz; G O Breault; J E Baer; J A Totaro
Journal:  J Pharmacol Exp Ther       Date:  1976-08       Impact factor: 4.030

6.  Bladder emptying in neonates.

Authors:  J Osborne; G Du Mont; M Beecroft; A B Ayres
Journal:  Arch Dis Child       Date:  1977-11       Impact factor: 3.791

Review 7.  Clincial pharmacokinetics in neonates.

Authors:  P L Morselli
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  Developmental patterns of renal functional maturation compared in the human neonate.

Authors:  B S Arant
Journal:  J Pediatr       Date:  1978-05       Impact factor: 4.406

9.  Metabolic disposition of methyldopa in hypertensive and renal-insufficient children.

Authors:  R F O'Dea; B L Mirkin
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

10.  A study of the disposition of alpha-methyldopa in newborn infants following its administration to the mother for the treatment of hypertension during pregnancy.

Authors:  H M Jones; A J Cummings; K D Setchell; A M Lawson
Journal:  Br J Clin Pharmacol       Date:  1979-11       Impact factor: 4.335

View more
  5 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 2.  The treatment of hypertension in pregnancy. Clinical pharmacokinetic considerations.

Authors:  C Knott
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

3.  Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.

Authors:  Meghan E Whalen; Richard Kajubi; Nona Chamankhah; Liusheng Huang; Francis Orukan; Erika Wallender; Moses R Kamya; Grant Dorsey; Prasanna Jagannathan; Philip J Rosenthal; Norah Mwebaza; Francesca T Aweeka
Journal:  Clin Pharmacol Ther       Date:  2019-07-22       Impact factor: 6.875

4.  Routes of meptazinol conjugation in the neonate.

Authors:  P S Dowell; D M Pierce; R A Franklin; P J Robson; M B Jackson
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 5.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.